Is there a role for therapeutic cancer vaccines in the age of checkpoint inhibitors?
Is there a role for therapeutic cancer vaccines in the age of checkpoint inhibitors?
复制标题
DOI：
10.1080/21645515.2016.1244149
复制
发表时间：
2017-03-04
影响因子：
4.8
通讯作者：
Dillman RO
中科院分区：
文献类型：
--
作者：
Dillman RO
由于单克隆抗体检查点抑制剂最近的成功，以及大多数治疗性癌症疫苗试验的令人失望的结果，人们质疑此类产品是否有任何潜在的作用。在我看来，答案是“是的”，基于以下几点：[1]存在持续未满足的临床需求，因为大多数患者不能从抗检查点治疗中获益，[2]有证据表明并非所有患者都对其肿瘤产生免疫应答，[3]有证据表明对自体肿瘤抗原的免疫应答可以通过患者特异性疫苗诱导，[4]来自检查点前时代的临床证据表明，这种患者特异性疫苗可以对生存产生积极影响，[5]已经获得监管批准的2种可用的治疗性疫苗在治疗益处方面非常有限。
Because of the recent success of monoclonal antibody checkpoint inhibitors, and the disappointing results of most therapeutic cancer vaccine trials, it has been questioned whether there is any potential role for such products going forward. In my opinion the answer is “yes” based on the following: [1] there is a persistent unmet clinical need because the majority of patients do not benefit from anti-checkpoint therapy, [2] there is evidence that not all patients make immune responses to their tumors, [3] there is evidence that immune responses to autologous tumor antigens can be induced by patient-specific vaccines, [4] there is clinical evidence from the pre-checkpoint era that suggests survival can be positively impacted by such patient-specific vaccines, and [5] the 2 available therapeutic vaccines that have received regulatory approval are quite limited in terms of their therapeutic benefit.